TROD Medical’s Prostate Focal Therapy Device EncageTM Advances in US and UK Clinical Studies

Leuven, Belgium: 16 June 2016 - TROD Medical NV, the medical device company developing tools for focal ablation announces completion of enrolment in its clinical study at two world-renown cancer research institutions, University College London (UCL) and New York University (NYU).

The clinical teams at NYU and UCL presented last month at the 111th American Urological Association's Annual Meeting (San Diego, CA), on patients treated with Encage. Together with a study running at the Moffitt Cancer Center (Tampa, Florida), over 40 patients have now been treated using Encage. Results not yet published show total tissue destruction in target ablation zones and very significant reduction of side effect (erectile dysfunction and urinary incontinence rates down to 0%).

More info on TROD Medical's website.


Next > Mainstay Medical announces € 30 million fundraising

Previous > FRX / Nofia used in New Bromine-Free Synthetic Hair Fibers